HIV

The FDA approved lenacapavir, which is the first approval of a drug in a new class of antiretrovirals for the treatment of HIV-1 called capsid inhibitors.

Although quality of life has significantly improved for patients with HIV, there are several factors influencing how we provide care and treat patients now and in the future.

Implants could produce and deliver monoclonal anti-HIV antibody therapy for at least 1 year.

Due to the correlation between virologic suppression and antiretroviral therapy adherence, understanding the impediments of adherence is of the utmost importance.

The findings could also help explain why certain comorbidities persist following other viral infections, including COVID-19.

The 2022 theme is “Putting Ourselves to the Test: Achieving Equity to End HIV.”

Study results show that patients with moderate or severe immune suppression should be considered a priority for additional vaccine doses and risk-reduction strategies.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Approximately 80% of all HIV infections among teens are from the gay and bisexual population.

Although fentanyl is potent and often deadly, it is not passively absorbed into the bloodstream.

Beth Macy, author of New York Times-bestselling book Dopesick and executive producer and writer on the Hulu series “Dopesick,” explains how FDA-approved drugs that treat opioid use disorder still aren’t getting into the hands of patients who need it most.

Investigational broadly neutralizing antibody shows promise as potential as a first-in-class treatment option for HIV.

ART also results in a faster decay of plasma HIV RNA and increased HIV CD8+T cell immunity compared with the treatment alone, investigators found.

New clinical outcomes from BICSTaR study indicate sustained impact of the therapy for individuals with HIV.

News research results in Zambia also find that early intervention in the form of antiretroviral therapies and better nutrition may help close the gap.

By targeting the viral conical core, these ARTs could disrupt the process of assembly and/or disassembly of the virus and result in its suppression.

Researchers suggest that all patients with HIV should be considered for additional vaccine doses, among other measures, to reduce their risk.

A presentation at the AMCP Nexus conference focuses on the health care disparities and pharmacotherapy options for gender affirmation.

A large collective of researchers may be one step closer to developing a vaccine against HIV after engineering a protein that triggers a widespread antibody response.

Research suggests that HIV risk-reduction interventions could help adolescent males who are attracted to the same sex—and part of a minority ethnic and racial group—decrease HIV-risk sexual behaviors in the short-term.

Research suggests that an HIV patient’s risk of heart attack increases with each passing decade, and this risk is nearly 3-fold among patients with HIV who are also positive for hepatitis C.

Program will start to distribute a free HIV self-test to people who enroll by early 2023.

Revised program will analyze the once-daily oral combination of doravirine 100 mg and a lower dose of islatravir in adults with HIV-1 infection.

A refundable state-level earned income tax credit was associated with a 21% reduction in high-risk HIV behavior among low-income women last year, suggesting that policy can reduce this burden.

Dolutegravir is a more recently approved ART that is a part of a once-a-day regimen found to be more effective, easier to tolerate, and less likely to create new drug resistance in people with HIV-1 compared with other antiretroviral drugs.

In New York’s medical cannabis program, research showed that patients’ preference around potency differed among users, regardless of their health conditions.

High rates of HIV can decrease with community-based support.

Last year, the majority of new drug approvals were for small molecules, including treatments for HIV, cancer, infections, heart and kidney disease, and neurological disorders.

The effective preventive treatment could reduce HIV rates but needs greater access and affordability, especially among Black and Latino populations, investigators contend.

Participants who initiated treatment with Biktarvy demonstrated superior hepatitis B virus (HBV) DNA suppression and HBV e-antigen seroconversion.